Bio-Path Investor Relations Material
Latest events
Q3 2024
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bio-Path Holdings Inc
Access all reports
Bio-Path Holdings Inc. is a biotechnology company focused on the development of RNAi-based therapies for cancer treatment. The company uses its proprietary DNAbilize® platform to design lipid-delivered RNAi therapeutics that target specific proteins involved in cancer cell survival and proliferation. Bio-Path’s lead programs focus on treating hematologic cancers such as leukemia and lymphoma. The company’s approach aims to provide innovative treatment options for patients with unmet medical needs in oncology. The company is headquartered in Bellaire, Texas, USA, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BPTH
Country
🇺🇸 United States